拉帕替尼
CAS号 | 231277-92-2 | 货号 | BCP01874 |
中文名 | 拉帕替尼 | ||
英文名 | Lapatinib | ||
中文别名 | |||
英文别名 | GSK572016; GSK-572016; GSK 572016; GW2016; GW-2016; GW 2016; | ||
分子式 | C29H26ClFN4O4S | 分子量 | 581.06 |
生物活性 | Lapatinib weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib inhibits the growth of both EGFR- and ErbB2-overexpressing cells. | ||
上下游产品 | 388082-78-8(二甲苯磺酸拉帕替尼) 388082-77-7(二对甲苯磺酸拉帕替尼) | ||
信号通路 | Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway | ||
靶 点 | EGFR HER2 |
Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer
购于瀚香生物(Biochempartner)的拉帕替尼(CAS:231277-92-2)被引用 |
mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer
购于瀚香生物(Biochempartner)的拉帕替尼(CAS:231277-92-2)被引用 |
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服:
- 全国免费电话:400-099-8200
瀚香生物(Biochempartner) 的所有产品和服务仅用于科学研究,禁止用于人体和治疗!